terazosin
- Product NDC
- 68788-8171
- 11-digit product format
- 687888171
- Labeler code
- 68788
- Product ID
- 68788-8171_933b040f-e49e-4ff9-a6f2-1124b97bbe57
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- terazosin
- Dosage form
- CAPSULE
- Route
- ORAL
- Labeler
- Preferred Pharmaceuticals Inc.
- Application
- ANDA075614
- Marketing category
- ANDA
- Marketing start
- 2022-04-25
- Substance
- TERAZOSIN HYDROCHLORIDE
- Active strength
- 2 mg/1
- Pharmacologic classes
- Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- terazosin
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| TERAZOSIN HYDROCHLORIDE | 2 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | D32S14F082 |
| Rxcui | 313217 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 68788-8171-3 | terazosin | 30 in 1 BOTTLE | CAPSULE | 30 | | 4 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 68788-8171 | TERAZOSIN CAPSULE [PREFERRED PHARMACEUTICALS INC.] | 3 | Current NDC, Legacy NDC, 1 package rows | 20240820_a78f74ce-1c53-41ea-878e-13674db10a67.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 68788-8171-3 | 68788817103 | 30 CAPSULE in 1 BOTTLE (68788-8171-3) | 30 capsule | 2022-04-25 | 0000-00-00 | No | No | Current |